| Abstrakt: |
A recent study conducted by researchers from Mayo Clinic in Rochester, Minnesota, explored the use of a mixed porcine-human bioengineered liver (MPH-BEL) as a potential treatment for post-resection liver failure (PRLF). The study compared the functional capacity of MPH-BEL grafts with fully human (FH-BEL) grafts using a porcine PRLF model. The results showed that the MPH-BEL treatment led to improved markers of liver function in PRLF, although platelet sequestration and immune activation were observed. The researchers concluded that further improvement in liver function could be achieved by seeding the biomatrix with human hepatocytes and reducing platelet sequestration. [Extracted from the article] |
